Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury: Industry-led perspective from EFPIA members of the EU Innovative Medicines Initiative Drug Liver Injury Project, MIP DILI
Year: 2017
Type: review
Institutions: Institut de Recherches Internationales Servier (France), AstraZeneca (United Kingdom), AbbVie (United States), UCB Pharma (Belgium), Lundbeck (Denmark), Merck KGaA, Darmstadt (Germany), Merck Healthcare KGaA, Darmstadt (Germany), Orion Corporation (Finland), Sanofi (France), Janssen (Belgium), AstraZeneca (Sweden), Eli Lilly (United States), GlaxoSmithKline (United Kingdom), University of Liverpool
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: closed
Funder: Innovative Medicines Initiative
OpenAlex ID: W2625358526
